Using fecal microbiota transplantation to treat advanced gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of fecal microbiota transplantation (FMT) capsules in combination with chemotherapy and anti-PD-L1 therapy for patients with advanced gastric cancer. It is a randomized, double-blind, placebo-controlled trial, meaning participants will be assigned to either receive the FMT capsules or a placebo without knowing which they are receiving. The study aims to determine if FMT can enhance treatment outcomes in patients with locally advanced, unresectable, or metastatic gastric adenocarcinoma. Participants must provide tumor tissue and have measurable disease to qualify.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Voluntarily participate in this study and provide written informed consent. Age ≥ 18 years , male or female. Pathological confirmed locally advanced, unresectable or metastatic gastric adenocarcinoma, esophagogastric junction adenocarcinoma.

Able and willing to provide tumor tissue. At least one measurable extracranial target lesion according to iRECIST. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Life expectancy ≥3 months.

Exclusion Criteria:

Presence of absolute contra-indications to FMT administration:Toxic megacolon;Inflammatory bowel disease;Anatomic contra-indications to colonoscopy;Colectomy Patient is currently participating and receiving other study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of this study intervention.

Currently under any form of systemic antibiotics. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (\> 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy two weeks prior to trial treatment. Patients receiving systemic steroids at physiologic doses are permitted to enroll assuming steroid dose is not above the acceptable threshold (\> 10 mg prednisone daily or equivalent).

Severe anaphylactic reaction to any food (food allergies). Had a severe hypersensitivity reaction to propofol. Has serious concomitant illnesses. The eligibility can be granted by the treating investigator on individual bases.

Has HIV infection or AIDS-related illness. Has active infection of HAV, HBV or HCV. Patients with a history of Hepatitis B/C infection who have received anti-viral therapy and are disease free may be considered for enrollment after discussion with Principal Investigator.

Patient has received a live vaccine within 4 weeks prior to the first dose of treatment. Seasonal influenza vaccines or COVID-19 vaccines for injection are generally inactivated virus vaccines and are allowed.

Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Females who are pregnant or breastfeeding. Active central nervous system (CNS) metastases and/or leptomeningeal involvement

Where it's running

• Changhai Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Xiangyu Kong, associate professor
• Email: xiangyukong185@hotmail.com
• Phone: 13564644397

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting Immunotherapy Response in Advanced Gastric Cancer using PET Imaging

  This study tests whether FAPI PET/CT and Grazytracer PET/CT can predict how advanced gastric cancer will respond to preoperative immunotherapy-based treatment.

  Recruiting Ruijin Hospital · Shanghai · NCT07824479

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Low-leucine diet with chemotherapy and immunotherapy for advanced stomach cancer

  This will test whether a low-leucine diet helps people with advanced gastric cancer respond better to combined chemotherapy and immunotherapy.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT07537348

• BHB810 in advanced gastric and GEJ cancer (early-phase)

  This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.

  Recruiting at 2 sites Phase 1/2 BigHat Biosciences, Inc. · Duarte, California and 2 other locations · NCT07529808

• Managing chemotherapy side effects with a smartphone symptom app plus telenursing

  This trial tests whether a smartphone symptom-reporting app combined with a standardized telenursing program helps adults starting first-cycle chemotherapy for gastric, lung, breast, or colon cancer manage treatment side effects.

  Recruiting at 4 sites Ulsan University Hospital · Busan and 4 other locations · NCT07405931

• QL1706 (Iparomlimab + Tuvonralimab) with SOX chemotherapy for untreated advanced or metastatic gastric or gastroesophageal junction cancer

  This trial will test whether adding QL1706 (two immunotherapy drugs) to SOX chemotherapy helps people with previously untreated advanced or metastatic gastric or gastroesophageal junction cancer get a better tumor response.

  Recruiting Phase 2 Beijing Friendship Hospital · Beijing, Beijing Municipality · NCT07315854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.